



CSE:SNN
OTCQX:SNNVF

Sunniva meaning: Gift of the Sun

A medicinal cannabis company

Disclaimer

IMPORTANT: YOU MUST READ THE FOLLOWING BEFORE CONTINUING

This presentation is not, and under no circumstances is to be construed as, a prospectus, or advertisement or a public offering of securities of Sunniva Inc. ("Sunniva" or the "Company").

This presentation contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, statements regarding Sunniva's plan to cultivate, produce and distribute a broad range of solutions focused on patients' needs and Sunniva's plans, timing and estimates of production for its facilities, are "forward-looking statements." Forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, among others, the risk factors included in the Sunniva's final prospectus dated November 16, 2017 (the "Prospectus"), including without limitation, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing state, local or other licenses and any inability to obtain all necessary governmental approvals licenses and permits to complete construction of its proposed facilities in a timely manner; engaging in activities which currently are illegal under US federal law and the uncertainty of existing protection from U.S. federal or other prosecution; regulatory or political change such as changes in applicable laws and regulations, including U.S. state-law legalization, particularly in California, due to inconsistent public opinion, perception of the medical-use and adult use marijuana industry, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth; Sunniva's limited operating history and lack of historical profits; reliance on management; and the effect of capital market conditions and other factors on capital availability; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with customers and suppliers. Readers are encouraged to the review the section titled "Risk Factors" in the Prospectus and Sunniva's other disclosure documents available on www.sedar.com. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. Although Sunniva has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. Sunniva assumes no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law.

The focus of Sunniva's business is the cannabis industry. The production, distribution, sale and use of marijuana and its derivatives are still restricted by law in some of the jurisdictions in which Sunniva intends to operate, including under federal law of the United States despite being legalized under some state law. These laws and their enforcement are in flux and vary dramatically from jurisdiction to jurisdiction. The enforcement of these laws and its affect on Sunniva and its business, employees, directors and shareholders are uncertain and accordingly involve considerable risk. This presentation contains information obtained by the Company from third parties, including but not limited to market data. The Company believes such information to be accurate but has not independently verified such information. To the extent such information obtained from third party sources, there is a risk that the assumptions made and conclusions drawn by the Company based on such representations are not accurate.

Cannabis-Related Practices or Activities are Illegal Under U.S. Federal Laws. The concepts of "medical cannabis" and "recreational cannabis" do not exist under U.S. federal law. The U.S. Federal Controlled Substances Act classifies "marihuana" as a Schedule I drug. Accordingly, cannabis-related practices or activities, including without limitation, the manufacture, importation, possession, use or distribution of cannabis are illegal under U.S. federal law. Strict compliance with state laws with respect to cannabis will neither absolve the Company of liability under U.S. federal law, nor will it provide a defense to any federal proceeding which may be brought against the Company. Any such proceedings brought against the Company may adversely affect the Company's operations and financial performance.

Sunniva Inc. – Quick Facts

- Founded by Dr. Anthony Holler and Leith Pedersen
- Experienced leadership team with a track record in healthcare
- Uniquely positioned in the largest legalized medical and recreational cannabis markets – California and Canada
- Vital products and services across three operational business units:
 - Sunniva Medical Inc. (Canada) / CP Logistics, LLC (US)** - State of the art purpose built greenhouse manufacturing facilities at scale
 - Natural Health Services Ltd.** - Specialized medical cannabis clinics
 - Full Scale Distributors, LLC [Vapor Connoisseur]** - Quality Vaporization Devices
- Construction underway for a modern, agri-technology greenhouse facility in California capable of producing over 100,000 kg of premium cannabis annually, once phase 1 and 2 are complete
- Received all required California temporary licenses to cultivate, process cannabis; will apply for annual state licenses within next four months
- Designs completed for purpose-built current Good Manufacturing Practice (cGMP) compliant greenhouse facilities in British Columbia capable of producing 100,000 kg of premium medical cannabis per year and over 25,000 kg of trim used for extraction

Investment Data

Canadian Listing	CSE:SNN
US Listing	OTCQX:SNNVF

Securities Data

Common Shares Outstanding	31,735,410
Warrants	1,996,240
Options	4,166,054
<u>Convertible Notes</u>	<u>2,495,028</u>
Fully Diluted Shares Outstanding	40,392,732

2018 Milestones

- Sunniva public listing on the CSE under symbol SNN
- Sunniva trading on the OTCQX under symbol SNNVF
- Executed 90,000 kg. supply agreement in Canada
- California extraction facility commences operations
- Closed CDN \$27.8M Bought Deal Public Offering
- Received all temporary state licenses in California

Better is Possible™

Sunniva Inc., through its subsidiaries, is a vertically integrated medical cannabis company operating in the two largest markets – **California** and **Canada**. Sunniva is committed to becoming one of the lowest cost producers delivering safe, high-quality cannabis products and services at scale.

We are working in pursuit of:

- Better cannabis products free of harmful pesticides
- Better cultivation through cGMP greenhouse design
- Better patient and doctor access to cannabis education
- Better therapeutic delivery devices

In a rapidly emerging and transformative industry, our promise is **Better is Possible™**.



Investment Highlights

- **Uniquely positioned** in the largest cannabis markets – **California** and **Canada**
- **Experienced Leadership Team with a track record in healthcare**
 - Management and Board focused on creating significant shareholder value
- **Vital products and services** across three operational business units:
 - State of the art purpose built greenhouse manufacturing facilities at scale
 - Specialized Cannabis Clinics
 - Quality Vaporization Devices
- **Revenues and cash flow** from acquisitions of Natural Health Services and Vapor Connoisseur
- **Strategic real estate partner;** non-dilutive construction financing allows for significant buildout
- **Regulatory Compliance** in all operating jurisdictions

CANADIAN MARKET

\$1.4 BN

EST. MEDICAL CANNABIS MARKET

750,000

EST. MEDICAL PATIENTS FORECAST BY 2019

269,502^(A)

CURRENT MEDICAL PATIENTS REGISTERED

\$7.0 BN

EST. COMBINED MEDICAL AND RECREATIONAL MARKET

102^(A)

LICENSED PRODUCERS

CALIFORNIA MARKET

\$2.8 BN

EST. CURRENT MEDICAL CANNABIS MARKET

2,500,000

EST. MEDICAL PATIENTS FORECAST BY 2019

760,000

EST. MEDICAL PATIENTS REGISTERED

\$10.0 BN

EST. COMBINED MEDICAL AND RECREATIONAL MARKET

VERY FEW

COMPLIANT LICENSED PRODUCERS

Source: New Frontier Data and Arcview Research
A. Health Canada as of April 24, 2018

Highly Experienced Management Team



Dr. Anthony (Tony) Holler, Co-founder, Chairman and CEO

Tony is the former CEO and founder of ID Biomedical which was one of the largest high quality, low cost manufacturers of flu vaccines acquired by GlaxoSmithKline in 2005 for \$1.7 billion. Former Chairman of Corriente Resources Inc. which was sold for approx. \$700 million to CRCC-Tongguan Investment Co. Current Chairman of CRH Medical Corporation which is a public company trading on the TSX and NYSE. Dr. Holler invests and takes an active role in every company and his expertise includes strategic planning, mergers and acquisitions, financing with a singular focus on increasing shareholder value.

Leith Pedersen, Co-founder, President

Former owner and CEO of Vida Wealth Management Bahamas, former Investment advisor at Canaccord Wealth Management and former Partner and Director at JF Mackie and Company, an independent brokerage firm in Calgary Alberta that managed capital in excess of \$2 billion for high net worth clients. Leith's expertise is corporate strategy, financing and mergers and acquisitions.

David Negus, CFO

Mr. Negus most recently served as the CFO of Luvo, Inc., a forward-thinking food company. Prior to his role at Luvo, Mr. Negus was Vice President, Corporate Controller at lululemon athletica. In his role at lululemon, Mr. Negus lead the finance team through their initial public offering and was responsible for their global financial reporting, accounting, tax, and treasury functions. As part of the lululemon leadership team, he played an integral role in the development and build out of a finance team that supported the business from a private company to a multi-billion dollar international organization.

Duncan Gordon, COO

Duncan has over 25 years experience as a manufacturing and supply chain expert, leading teams responsible for large scale projects with a focus on engineering, continuous improvement, procurement, logistics, production and distribution. Former head of manufacturing and supply chain management at Kudu Industries which was privately sold in 2015.

Vinayak Shastry, President and CEO, Sun CA Holdings, Inc.

Prior to Sunniva, Mr. Shastry was an executive with Foundation Partners, a California based real estate development company. Prior to Foundation Partners, Mr. Shastry served as the Chief Financial Officer of IDEA Solutions, a software services company headquartered in San Jose, California. Earlier in his career, Mr. Shastry worked in private equity and investment banking at TPG Capital and Morgan Stanley, respectively

Ben Rootman, VP Legal, Compliance and Regulatory Affairs

Ben has over 10 years of experience providing legal, compliance and regulatory advice to private and public companies in the real estate, finance, information technology and oil and gas sectors focusing on corporate/commercial and securities law.

Board of Directors



Dr. Anthony Holler, Co-founder, Chairman, CEO and Director

Leith Pedersen, Co-founder, President and Director

Todd R. Patrick, Lead Director

Todd brings 30 years of senior executive experience in building healthcare companies from the ground up. With expertise in finance, intellectual property, strategy and leadership, Todd has been involved with several start-ups as either CEO or as an active investor/board member. In these positions, Todd has helped raise over \$600 million in equity/debt capital and participated in several merger and acquisition transactions. Todd is currently the President and CEO of C3J Therapeutics, Inc., a Los Angeles-based biotechnology company where he has raised over \$125 million in equity capital. Prior to joining C3J, Todd spent 11 years as President of ID Biomedical Corporation until its \$1.7 billion acquisition by GlaxoSmithKline.

Norm Mayr, Director, Audit Committee Chairman

Norm Mayr is a retired Audit Partner having spent 38 years in public practice with KPMG. He was the Risk Management and Professional Practice Partner for the Greater Vancouver Area practice of KPMG for the last 18 years of his career. He was a founding member of the CICA Accounting Standards Board, and a member of the Canadian Advisory Group to the International Accounting Standards Committee. He currently serves as Chair of the Investigation Committee for the Chartered Professional Accountants of British Columbia.

Ian Webb, Director

Former Director of ID Biomedical and Director of CRH Medical Corp. Former senior corporate law partner of Borden Ladner Gervais LLP, one of Canada's largest law firms, whose practice encompassed mergers and acquisitions, corporate and securities law with an emphasis on the legal requirements of public companies and their boards.

Dan Vass, President of Natural Health Services (NHS) and Director

Founder and President of NHS which operates boutique cannabis clinics in Canada with over 75,000 patients and growing. The NHS focus is on underserved patient needs and education for access to medical marijuana in a physician approved, safe and healthy environment. NHS is a medical centric corporation offering high levels of patient care, superior service and improved quality of life for its patients. NHS is grower agnostic, working closely with all Licensed Producers to ensure the patient comes first, creating reasonable access for all Canadians.

Michael Barker, Director

Founder of Barker Pacific Group (BPG), a firm of experienced real estate professional active in the acquisition, development, construction management, and asset management of major commercial projects. Founded in 1983, the company specializes in the development and acquisition of institutional quality office, industrial, and residential projects. As a developer, BPG has completed, developed, or redeveloped in excess of \$2.5 billion in commercial projects. The company enjoys close relationships with major corporate and institutional partners who commend the BPG management team's commitment to excellence, entrepreneurial vision, business acumen, and personal integrity.

Luke Stanton, Director

Luke K. Stanton is an attorney and of founder the Frontera Law Group, a leading firm in the state of California focusing on cannabis business. Frontera Law Group specializes in business law, corporate law, medical marijuana compliance, state licensing, multi-state expansion projects, and criminal defense. Frontera represents a host of best in class cannabis companies, brands, products and ancillary service providers. Mr. Stanton is a member of the National Organization for the Reform of Marijuana Laws Legal Committee (NORML), Americans for Safe Access (ASA), Drug Policy Alliance (DPA), Marijuana Policy Project (MPP), Coalition for Cannabis Policy Reform (CCPR), and Reform California.

How we are addressing the needs of the current Cannabis Industry

Sunniva is committed to providing:

- Safe, pesticide free, high quality, reproducible cannabis medicines
- Accessibility for patients seeking experienced cannabis doctors and education on what products to use via ownership of Natural Health Services
- Patients with safe and quality medical devices and drug delivery formats
- Best practices, audits and regulatory compliance across all business units

Sunniva Operating Divisions:

Sunniva cGMP* Greenhouses



Cultivation at Scale

CALIFORNIA
CANADA*****

Natural Health Services



Specialized Cannabis Clinics

CANADA

Vapor Connoisseur



Quality Vaporization Devices

NORTH AMERICA

* Current Good Manufacturing Practice standards

** California designed cGMP Campus via 100% ownership of CP Logistics LLC; broke ground November 2017

*** Canada designed cGMP Campus via 100% ownership of Sunniva Medical Inc., has not commenced, anticipated construction commencement - Early 2018

The Sunniva Campus cGMP Facility

Cathedral City, California: Phase One



Sunniva dispensary within the facility



Construction commenced November 2017 and estimated to be operational Q3 2018

The Sunniva Campus cGMP Facility

Cathedral City, California: Phase One



- **Phase One:** 325,000 sq. ft. facility | 8 x 22,000 sq. ft. flower canopy licenses
- **Phase Two:** 165,000 sq. ft. facility | 8 x 10,000 sq. ft. flower canopy licenses
- **Sunniva branded products** and **private label solution** for **leading brands**





The Sunniva Campus cGMP Facility

Cathedral City, California: Phase One

- Designed to be a **state-of-the-art focused* cGMP compliant** greenhouse and manufacturing facility
- **Low cost, high quality**, consistent and pesticide free cannabis-based medicines
- Estimated **50%** of the facility cultivation initially manufactured into **higher margin extracted products**
- Negotiating letters of intent with **sophisticated distribution networks**
- **Long term supply contract negotiations** commenced with leading brands for private label services
- **Conditional Use Permit** received October 4, 2017 and construction commenced November 2017

*Focused – Foundation of Cannabis Unified Standards





The Sunniva Campus

Cathedral City, California: **Phase One***

Cultivation at Scale

325,000 SQ FT

LICENSED FACILITY SIZE TO MANUFACTURE AND SELL IN CALIFORNIA

(PHASE 2: ADDITIONAL 165,000 SQ FT)


60,000+ KG **

PREMIUM CANNABIS PRODUCED PER ANNUM AT CAPACITY


(PHASE 2: 40,000+ KG) **



State-of-the-art cGMP greenhouse harnessing natural power of the sun




Recycled water



“Priva” environmental micro-climatic controls



Pharmaceutical quality product, low cost, scalability



Estimated less than \$1.00/gram operating costs



Automation and robotics throughout including black-out curtains

*Conditional Use Permit received October 2017

*Construction commenced November 2017 and estimated to be operational Q3 2018

** Base case annual production estimate and includes dried trim for extractions



Near Term Production

“Sun-Oil” Extraction Facility

Cathedral City, California

- **Producing** oils for existing device customers
- Manufacturing facility for **cannabis extracts**
- **Received state** temporary **license** for **volatile** and **non-volatile** extraction - **January 2018**
- **Genetics** for the larger Sunniva Greenhouse facility
- **Systems and training** for Sunniva workforce
- **500 lbs/day** of Bio mass capacity for extractions



The Sunniva Canada Campus

BC, Canada

Future Sunniva cGMP Greenhouse and Manufacturing Facilities*

- Sunniva Medical Inc. is in the review stage under Health Canada's Access to Cannabis for Medical Purposes Regulations (ACMPR)
- **Unique, scalable operations** in Canada to supplement the flagship Sunniva California Campus
- Business model to **sell up to 75% of production via long term supply contracts** and retain **25% for NHS medical patients**
 - Planned **700,000+ sq. ft.** cGMP greenhouses
 - Estimated **100,000+ Kg/year** production capacity



* Construction of the Canadian cGMP Facilities estimated to commence early 2018



Barker Pacific Group, Inc., (BPG) is a firm of experienced real estate professionals active in the acquisition, development, construction management, and asset management of major commercial projects. Founded in 1983, the company specializes in the development and acquisition of institutional-quality office, industrial, and residential projects. As a developer, BPG has completed, developed, or redeveloped in excess of \$2.5 billion in commercial projects. The company enjoys close relationships with major corporate and institutional partners who commend the BPG management team's commitment to excellence, entrepreneurial vision, business acumen, and personal integrity.

Strategic infrastructure and Financial Partner: Barker Pacific Group

Strategic financing partner and Sunniva investor

- Finance, build and lease facilities to Sunniva
- Facilitates accelerated growth for capacity build out with **minimal dilution**
- Purpose built cGMP Greenhouse facilities





NaturalHealth
Services

Specialized Cannabis
Clinics

Natural Health Services Canada

- **Rapidly growing** cannabis clinic network in Canada
 - 96,000* active patients and growing
 - Long term relationship with patients due to quality of physician-patient experience
- **Operates 8 clinics** and education centres in Canada*
 - Recently expanded in Ontario and Manitoba
 - **21 physicians** and **2 nurse practitioners**
 - **Hired a medical director focused on recruitment and pharmacies**
- Top tier customer base – **Provincial Healthcare Authorities**

*As of April 24, 2018





NaturalHealth
Services

Specialized Cannabis
Clinics

Natural Health Services

Canada

- **Proprietary Spark software** connects Licensed Producers (LPs) to physicians and patients
 - Integrates into LPs ERP systems
 - Software-as-a-service revenue model
 - Capture, retain and track patients
 - Better experience for patients and LPs
- **Spark Patient Software** application launched in February 2017
- **27 integrated Licenced Producers** to date* utilizing software

* As of April 24, 2018





VAPOR
CONNOISSEUR

Quality Vaporization
Devices

Vapor Connoisseur*

- One of the **largest private label** cannabis device providers in North America
- Provides **quality vaporization devices**, cartridges, accessories and packaging to over 80 brands
 - Sunniva to offer full procurement **extraction white label services** to some of these leading brands in California
- Developing **proprietary** Sunniva branded vaporization devices and custom cartridges

* Full Scale Distributors, LLC operates as the brand Vapor Connoisseur



Sunniva cGMP Greenhouses CALIFORNIA / CANADA



Natural Health Services CANADA



Vapor Connoisseur NORTH AMERICA



- Low cost, high quality consistent medicines at scale
- California: Large-scale advantage
- Strong real estate partner to finance facilities
- California broke ground November 2017
- Canada license application in the review stage
- Received all temporary state licenses in California

- Experienced cannabis doctors and educators
- 96,000 active current patients
- Expanded to 8 clinic locations
- Integrated Spark software with 27 LP's to manage patients
- Potential future retail outlets

- Producing quality vaporization devices for leading brands
- Offers existing brands full procurement private label services
- New product development engine
- Focus on design and user experience

Achievements and Milestones

2017

- **Raised CDN \$51 million prior to listing**
- **3 Acquisitions closed February 2017**
- **NHS clinic expansion to 8 locations**
- **NHS reaches 75,000+ active patients, 21 physicians and 2 nurse practitioners**
- **NHS medical software integrated with 25 LP's**
- **California extraction facility receives city licenses**
- **Received CUP permit approval for California Campus**
- **California facility broke ground - November 2017**
- **California - Long term supply contract negotiations commenced** with leading brands and distributors
- **Canada - ACMPR license application in the review stage**
- **November 17, 2017 - Final prospectus** receipted by the securities commissions

2018

- **Sunniva public listing** on the **CSE** under **symbol SNN**
- **Supply contract negotiations** in Canada and California
- **Sunniva California Campus** - Expected completion Q3
- **Sunniva Canada Campus** - Anticipate to **break ground** on **700,000 sq. ft. cGMP greenhouse facility** in British Columbia
- **Sunniva trading** on the **OTCQX** under **symbol SNNVF**
- **Executed 90,000 kg. supply agreement** in **Canada**
- **California extraction facility commences operations**
- **Closed CDN \$27.8M Bought Deal Public Offering**
- **Received all temporary state licenses** in **California**



Current Capital Structure

	# Shares
Common Shares Outstanding	31,735,410
Warrants	1,996,240
Options	4,166,054
Convertible Notes	2,495,028
<hr/>	
Fully Diluted Shares Outstanding	40,392,732



sunniva

Better is Possible™